New injection shows promise for postpartum depression

NCT ID NCT02942004

Completed Symptom relief Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called SAGE-547 (brexanolone) given as a 60-hour intravenous infusion to 138 women with severe or moderate postpartum depression. The goal was to see if it could quickly reduce depressive symptoms compared to a placebo. Results showed that the drug significantly improved depression scores within days, offering a potential new option for new mothers struggling with this condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAGE-547 (brexanolone) injection
What this could lead to: If successful, this could provide a fast-acting treatment option for women suffering from postpartum depression, reducing symptoms within days.
What could go wrong: This is a completed Phase 3 trial, but results may not apply to all women. Side effects and individual responses vary, and the drug requires intravenous infusion in a medical setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postpartum depression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTPARTUM DEPRESSION

Contacts and locations

Locations

Sage Investigational Site

Chandler, Arizona, 85226, United States
Sage Investigational Site

Rogers, Arkansas, 72758, United States
Sage Investigational Site

Lemon Grove, California, 91945, United States
Sage Investigational Site

Orange, California, 92868, United States
Sage Investigational Site

Ventura, California, 93003, United States
Sage Investigational Site

Gainesville, Florida, 32607, United States
Sage Investigational Site

Miami, Florida, 33147, United States
Sage Investigational Site

Miramar, Florida, 33027, United States
Sage Investigational Site

Orlando, Florida, 32807, United States
Sage Investigational Site

Pensacola, Florida, 32502, United States
Sage Investigational Site

Pinellas Park, Florida, 33782, United States
Sage Investigational Site

Atlanta, Georgia, 30331, United States
Sage Investigational Site

Hoffman Estates, Illinois, 60169, United States
Sage Investigational Site

Wichita, Kansas, 67226, United States
Sage Investigational Site

Edgewood, Kentucky, 41017, United States
Sage Investigational Site

Owensboro, Kentucky, 42303, United States
Sage Investigational Site

Boston, Massachusetts, 02114, United States
Sage Investigational Site

Boston, Massachusetts, 02115, United States
Sage Investigational Site

Flowood, Mississippi, 39232, United States
Sage Investigational Site

Marlton, New Jersey, 08053, United States
Sage Investigational Site

Glen Oaks, New York, 11004, United States
Sage Investigational Site

Chapel Hill, North Carolina, 27514, United States
Sage Investigational Site

Charlotte, North Carolina, 28211, United States
Sage Investigational Site

Raleigh, North Carolina, 27612, United States
Sage Investigational Site

Columbus, Ohio, 43210, United States
Sage Investigational Site

Dayton, Ohio, 45417, United States
Sage Investigational Site

Philadelphia, Pennsylvania, 19104, United States
Sage Investigational Site

Houston, Texas, 77030, United States
Sage Investigational Site

Houston, Texas, 77058, United States
Sage Investigational Site

Richardson, Texas, 75080, United States
Sage Investigational Site

San Antonio, Texas, 78229, United States
Sage Investigational Site

Orem, Utah, 84058, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.